Tumor markers, explained: what they are and the one thing almost everyone gets wrong

A tumor marker is a protein that both cancer cells and normal cells make, measured from a blood sample. It is not a cancer test. Doctors mostly use these numbers to watch a cancer that has already been diagnosed, checking whether treatment is working or whether the cancer has come back, because a high result is usually not cancer and a normal result does not rule it out.

What are tumor markers?

Tumor markers are anything present in or produced by cancer cells or other cells of the body in response to cancer or certain benign (noncancerous) conditions that provides information about a cancer, such as how aggressive it is, whether it can be treated with a targeted therapy, or whether it is responding to treatment.National Cancer Institute, Tumor Markers in Common Use, 2024

The same protein appears in cancer and in "certain benign conditions," meaning harmless (noncancerous) states, so the number cannot tell those two apart on its own. ¹ That is why a tumor marker is a monitoring tool, not a verdict. It carries information about a cancer that is already known, such as whether treatment is shrinking it, far better than it answers the question "do I have cancer at all."

The same pattern holds across the list. CEA is a colorectal-cancer monitoring marker that smoking alone can push above the nonsmoker range, and CA-125 rises with a period, endometriosis, or fibroids long before you get anywhere near cancer.

Does a high tumor marker mean cancer?

No. A high tumor marker most often reflects a benign condition, not cancer, because healthy cells make these proteins too. CEA, for example, climbs in colorectal, pancreatic, gastric, lung, breast, and thyroid cancers and also in inflammatory bowel disease, pancreatitis, liver disease, and COPD, so a raised value cannot even name which organ it came from. ⁵ The clearest example is the prostate marker.

That single line explains most raised PSA results. A bigger PSA reading often means a bigger or irritated prostate, not a tumor. A high marker is a reason to ask the clinician who ordered it for context, not a number to panic over.

Can a blood test detect cancer?

Standard tumor marker blood tests cannot reliably detect cancer in a healthy person, which is why doctors do not use them that way. A good screening test needs two things at once: it has to catch real cancers (sensitivity, how rarely it misses) and rarely flag healthy people (specificity, how rarely it cries wolf). Tumor markers fail both bars. Many cancers never raise them, so a normal result misses real disease, and many harmless conditions do raise them, so a high result sends healthy people toward scans and biopsies they did not need. ¹ A blood number that looks worrying still has to be confirmed with imaging and usually a biopsy before anyone can say what it is.

Why screening healthy people backfires

When a test flags many people who turn out to be fine, the harm is a cascade of repeat blood draws, imaging, and biopsies, each with its own risk and cost, chasing numbers that were benign all along. The clearest way to see the trade-off is to line up the two jobs a blood test can do.

That is the strongest test of the idea we have. The UKCTOCS trial recruited more than 200,000 women; the roughly 50,000 assigned to annual CA-125 screening were followed for about 16 years. It caught some cancers earlier, and still ovarian cancer deaths did not drop. ⁴ Part of the reason is baked into the marker: CA-125 is raised in only about half of early-stage ovarian cancers, so it misses many of the ones screening is supposed to catch. ⁶

PSA, the one debated exception

PSA is the only tumor marker seriously used to screen, and even there the guidance stops short of a blanket yes. The US Preventive Services Task Force grades PSA screening for men aged 55 to 69 as an individual choice to weigh with a clinician (grade C) and recommends against routine screening for men 70 and older (grade D). ² The reason it stays a shared decision is that no PSA level settles anything: in the Prostate Cancer Prevention Trial, about 15 percent of men with a PSA of 4.0 ng/mL or below still had prostate cancer on biopsy. ³ In the 4 to 10 gray zone, a follow-up test (called a reflex test) such as free PSA or the free-to-total PSA ratio can help weigh whether a biopsy is worth it, but that is a conversation with a clinician, not a self-read from a single number. This page does not recommend for or against getting screened; that is yours to decide with a clinician who knows your history.

How these tests are run

Most tumor markers are a simple blood draw, usually with no fasting needed, and they are ordered on their own rather than tucked into a routine wellness panel. During monitoring, the same marker is repeated on a schedule the treating clinician sets so the trend can be read across visits, not from one snapshot. There is no routine tumor-marker check for healthy people with no symptoms, and a raised value in someone with no diagnosis is worked up with context and often a repeat before anything else happens.

What to do with a raised result

1. 1Do not panicA single raised tumor marker is far more often a benign condition than cancer, and one value out of context rarely means much.
2. 2Ask the clinician who ordered itAsk what the result is being compared against (your own earlier baseline, or a lab reference cutoff) and why the test was ordered in the first place.
3. 3Ask about a repeat and a trendFor monitoring, the direction over weeks or months carries the signal, so a single number is usually repeated before it changes anything.
4. 4Bring your historyA recent infection, an exam, pregnancy, smoking, and liver or bowel conditions all move these numbers, so context changes the read.

Further reading

LifeFrom membershipWant your own markers read in context, not just flagged high or low? Start with a full LifeFrom panel and get every result explained against your own history.Get started